Abstract：Objective: To explore the relationship between levels of plasma homocysteine (Hcy), vascular cell adhesion molecule-1 (VCAM-1) and N-terminal pro-brain natriuretic peptide (NT-proBNP) and prognosis of intravenous thrombolysis in patients with acute ischemic stroke (AIS). Methods: A retrospective analysis was performed on clinical data of 116 patients with AIS. The levels of plasma Hcy, VCAM-1 and NT-proBNP before treatment were compared among patients with different short-term efficacy of different intravenous thrombolysis [National Institutes of Health Stroke Scale (NIHSS) ] and long-term prognosis [modified Rankin scale (mRS) ]. The correlation between the above indicators and short-term NIHSS score reduction and long-term mRS score was analyzed. The receiver operating characteristic (ROC) curve was used to evaluate the efficacy of the above indicators in predicting long-term prognosis. Results: There was a significant difference in plasma Hcy level among patients with different reductions of short-term NIHSS score (P<0.05), but there were no significant differences in the levels of plasma VCAM-1 and NT-proBNP (P>0.05). The levels of plasma Hcy, VCAM-1 and NT-proBNP in patients with long-term mRS>2 points were significantly higher than those in patients with long-term mRS≤ 2 points (P<0.05). The plasma Hcy level was significantly negatively correlated with reduction of short-term NIHSS score (r<0, P<0.05), and the levels of plasma VCAM-1 and NT-proBNP were significantly correlated with reduction of short-term NIHSS score (P>0.05). The levels of plasma Hcy, VCAM-1 and NT-proBNP were significantly positively correlated with long-term mRS scores (r>0, P<0.05). The cut-off values of long-term poor prognosis predicted by plasma Hcy, VCAM-1 and NT-proBNP were ≥19.64 μmol/L, ≥994.01 ng/mL and ≥526.02 ng/L, and the values of area under the ROC curve were significantly smaller than those of combined prediction (P<0.05). Conclusion: The levels of plasma Hcy, VCAM-1 and NT-proBNP in AIS patients are closely related to the prognosis of intravenous thrombolysis. Early detection has high clinical reference value.
刘宏为, 蒋艳荣. 急性缺血性脑卒中患者Hcy VCAM-1及NT-proBNP水平与静脉溶栓预后的相关性分析[J]. 河北医学, 2020, 26(3): 389-392.
LIU Hongwei, JIANG Yanrong. Correlation between Hcy VCAM-1 and NT-proBNP Levels and Prognosis of Intravenous Thrombolysis in Patients with Acute Ischemic Stroke. HeBei Med, 2020, 26(3): 389-392.
[1] Sun W, Ou Q, Zhang Z, et al. Chinese acute ischemic stroke treatment outcome registry (CASTOR): protocol for a prospective registry study on patterns of real-world treatment of acute ischemic stroke in China[J]. BMC Complement Altern Med, 2017, 17(1):357. [2] 吴卓华,杨华杰,黄翔,等.脑卒中患者院内急诊救治延迟的现状及其影响因素研究[J].中国全科医学,2017,20(11):1374~1378. [3] Dong Q, Dong Y, Liu L, et al. The Chinese Stroke Association scientific statement: Intravenous thrombolysis in acute ischaemic stroke[J]. Stroke Vasc Neurol, 2017, 2(3):147~159. [4] 王志,金庙通,杨建邦.脑梗死患者血清miR-181c、miR-128b表达水平及其与90天预后的相关性[J].中国动脉硬化杂志,2019,27(6):517~521. [5] 中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组.中国急性缺血性脑卒中诊治指南2018[J].中华神经科杂志,2018,51(9):666~682. [6] Jeyaseelan RD, Vargo MM, Chae J. National institutes of health stroke scale (NIHSS) as an early predictor of poststroke dysphagia[J]. PM&R, 2015, 7(6):593~598. [7] Broderick JP, Adeoye O, Elm J. Evolution of the modified rankin scale and its use in future stroke trials[J]. Stroke, 2017, 48(7):2007~2012. [8] Zhong C, Xu T, Xu T, et al. Plasma homocysteine and prognosis of acute ischemic stroke: a gender-specific analysis rrom CATIS randomized clinical trial[J]. Mol Neurobiol, 2017, 54(3):2022~2030. [9] 郝攀.Hcy、NT-proBNP、D-dimer联合检测对急性脑梗死诊断的应用价值[J].标记免疫分析与临床,2019,26(2):212-215,233. [10] Tu WJ, Ma GZ, Ni Y, et al. Copeptin and NT-proBNP for prediction of all-cause and cardiovascular death in ischemic stroke[J]. Neurology, 2017, 88(20):1899~1905.
2020, Vol. 26 
冀公网安备13080202000677号